The abstract is read at the publisher; the summary is JClub's.
In adults with non-dialysis CKD stages G1–G5 already on ACEi/ARB, adding a thiazide diuretic was linked to lower cardiovascular event risk than calcium channel blockers, β-blockers, or loop diuretics.
- Why it matters: Guidelines for CKD hypertension do not specify which second drug class to use when extra blood pressure lowering is desired, leaving uncertainty about downstream cardiovascular and kidney outcomes.
- What they did: Using a target trial emulation of Veterans Health Administration outpatient data (2010–2016), adults initiating a second antihypertensive (thiazide, loop, calcium channel blocker, or β-blocker) were followed for a median 1282 days, with covariates included.
- The result: Compared with thiazide diuretics, cardiovascular events were higher with calcium channel blockers (aHR 1.18, 95% CI 1.15–1.22), β-blockers (aHR 1.63, 95% CI 1.58–1.67), and loop diuretics (aHR 1.97, 95% CI 1.90–2.04), and kidney outcomes were also higher for calcium channel blockers (aHR 1.42, 95% CI 1.33–1.52), β-blockers (aHR 1.13, 95% CI 1.06–1.21), and loop diuretics (aHR 1.98, 95% CI 1.83–2.15).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.